Persistent COVID-19 Symptoms in Minia
1 other identifier
observational
189
1 country
1
Brief Summary
Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 10, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 10, 2024
CompletedFirst Submitted
Initial submission to the registry
January 19, 2025
CompletedFirst Posted
Study publicly available on registry
January 22, 2025
CompletedJanuary 22, 2025
January 1, 2025
2.5 years
January 19, 2025
January 19, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Long COVID-19 has been an increasingly prevalent concern in the medical community for the last two years and is still a burden on the healthcare system worldwide
Constitutional and neurological manifestations are two of the most persistent symptoms. Lack of appropriate levels of awareness about long COVID-19, as well as the tendency of patients in this demographic to self-medicate are leading causes of the underreporting of long COVID-19 symptoms in this region
2years
Eligibility Criteria
This is a cross-sectional observational retrospective survey study in which we collected information about any persistent or new symptoms after recovery from COVID-19. The average time after recovery from COVID was 6 months at the time of patient interviews, and the median duration of symptoms was 14 days. We collected various patient data including their medical history before COVID-19, treatments they received during their illness, and self-reported use of unprescribed antibiotics in home-isolated patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Marwa
Al Fayyum, 63111, Egypt
Related Publications (1)
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
PMID: 33753937RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
January 19, 2025
First Posted
January 22, 2025
Study Start
March 10, 2021
Primary Completion
September 10, 2023
Study Completion
September 10, 2024
Last Updated
January 22, 2025
Record last verified: 2025-01